ADMA — ADMA BIOLOGICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1368514 ·
Last close
$10.33
Market Cap
$2.31B
52W High
$20.46
52W Low
$7.21
ADV30
2,912,673
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 124,395,000 | 86,277,000 | 52,445,000 | 37,822,000 | 684,210,000 | 136,020,000 | 276,002,000 |
| Mar 2026 | 114,493,000 | 80,750,000 | 50,294,000 | 45,328,000 | 665,184,000 | 138,153,000 | 274,859,000 |
| Dec 2025 | 139,163,000 | 88,816,000 | 62,751,000 | 49,379,000 | 624,242,000 | 87,630,000 | 146,922,000 |
| Sep 2025 | 134,224,000 | 75,626,000 | 51,012,000 | 36,428,000 | 568,687,000 | 61,385,000 | 137,501,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$136,720,000
Investing CF
$-14,496,000
Financing CF
$-76,489,000
CapEx
$-20,496,000
Dividends Paid
—
Buybacks
$-187,185,000
EPS Diluted TTM
$0.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,503,000
Inventory
$239,313,000
Receivables
$138,231,000
ST Investments
—
EBIT TTM
$225,299,000
Pretax Income TTM
$216,474,000
Interest Exp TTM
$8,825,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$512,275,008
EBITDA
$224,192,992
Free Cash Flow
$54,755,376
Enterprise Value
$43,814,924,288
Total Cash
$55,921,152,000
Total Debt
$97,668,702,208
Shares Out
223,984,680
Trailing EPS
$0.70
Book Value
$1.81
ROE
41.9%
ROA
21.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 510,173,000 | 191,443,000 | 146,930,000 | 624,242,000 | 146,922,000 | 477,320,000 | 50,396,000 |
| Dec 2024 | 426,454,000 | 138,983,000 | 197,673,000 | 488,678,000 | 139,660,000 | 349,018,000 | 118,672,000 |
| Dec 2023 | 258,215,000 | 21,632,000 | -28,239,000 | 329,182,000 | 193,976,000 | 135,206,000 | 8,800,000 |
| Dec 2022 | 154,080,000 | -39,365,000 | -65,904,000 | 348,461,000 | 196,487,000 | 151,974,000 | -59,508,000 |
TTM Snapshot
Revenues TTM
$509,864,000
NetIncome TTM
$165,354,000
OpCashFlow TTM
—
Assets (Latest)
$665,184,000
Forward EPS
$0.94
Max Pain — expiry 2026-11-20
max pain strike: $10.00 · spot: $10.36 · call oi: 27,158 · put oi: 9,265
Expected Move to 2026-11-20:
±$2.47
(23.89%) —
implied range
$7.88 –
$12.83
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.12B | $8.29 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $2.11B | $3.95 | — |
| BEAM | Beam Therapeutics Inc. | $2.54B | $24.60 | — |
| VCEL | Vericel Corp | $2.05B | $40.05 | — |
| ALVO | Alvotech | $2.02B | $5.67 | — |
News headlines (Yahoo Finance, 1h cache)
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
2026-10-08 20:50 · Yahoo
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
2026-10-08 12:00 · Yahoo
ADMA Biologics (ADMA), Why Is It Back In The Spotlight?
2026-09-27 13:06 · Yahoo
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
2026-09-24 20:50 · Yahoo
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
2026-09-24 12:30 · Yahoo
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
2026-09-18 21:50 · Yahoo
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-09-11 21:45 · Yahoo
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-09-10 21:50 · Yahoo
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
2026-09-08 13:30 · Yahoo
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
2026-09-04 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.